CDKN2A W110*

CI-VAR-00004667Explore in graph →NP_000068.1:p.Trp110TerNM_000077.4:c.330G>AClinVar 376303 CIViC 1521 rs121913389

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
CDKN2A W110*	Palbociclib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4523 In an in vitro study, a melanoma CHL1 cell line expressing CDKN2A W110* nonsense mutation (endogenous) demonstrated sensitivity to palbociclib treatment (GI50: 192nM). Sensitivity was determined by as… (full text at CIViC) PMID 24495407 · Young et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376303	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Lip and oral cavity carcinoma; Hereditary cancer-predisposing syndrome; Familial melanoma; Melanoma-pancreatic cancer syndrome; Neoplasm; CDKN2A-related disorder	germline/somatic	7	Dec 02, 2025	clinvar